Bright Minds Biosciences Announces Resignation of Board Member
January 09, 2023 16:05 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Closing of Non-Brokered Private Placement
December 02, 2022 19:07 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Announces Non-Brokered Private Placement
November 28, 2022 06:50 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Appoints Drug Development Executive Mark A. Smith M.D., Ph.D. as Chief Medical Officer
November 23, 2022 11:35 ET
|
Bright Minds Biosciences
-- Dr. Smith is a 20-year pharmaceutical industry veteran with extensive central nervous system (“CNS”) clinical development expertise -- VANCOUVER, British Columbia, Nov. 23, 2022 (GLOBE NEWSWIRE)...
Bright Minds Biosciences Announces Appointment of Doug Williamson to Board of Directors
September 07, 2022 06:50 ET
|
Bright Minds Biosciences
NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR FOR RELEASE, PUBLICATION, DISTRIBUTION OR DISSEMINATION DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES VANCOUVER, British...
Bright Minds Biosciences Initiates Dosing in Phase I Clinical Trial of BMB-101 for Dravet Syndrome
August 31, 2022 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Aug. 31, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Closing of $4 Million Unit Offering
August 30, 2022 15:35 ET
|
Bright Minds Biosciences
THIS NEWS RELEASE IS INTENDED FOR DISTRIBUTION IN CANADA ONLY AND IS NOT AUTHORIZED FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. VANCOUVER, British...
Bright Minds Biosciences Comments on Recent Trading Activity
August 18, 2022 15:34 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, Aug. 18, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences Announces Changes to its Executive Leadership Team, Marking the Transition to a Development Organization
June 27, 2022 06:50 ET
|
Bright Minds Biosciences
VANCOUVER, British Columbia, June 27, 2022 (GLOBE NEWSWIRE) -- Bright Minds Biosciences (“Bright Minds,” “BMB” or the “Company”) (Nasdaq: DRUG) (CSE: DRUG), a biotechnology company focused on...
Bright Minds Biosciences to Host Key Opinion Leader Symposium on Dravet Syndrome
May 12, 2022 06:50 ET
|
Bright Minds Biosciences
-- Review of Phase I ready BMB-101 and upcoming milestones -- -- Webcast to be held on May 19, 2022, 4:00pm ET -- VANCOUVER, British Columbia, May 12, 2022 (GLOBE NEWSWIRE) -- Bright Minds...